These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18175337)

  • 1. Placebo influences on dyskinesia in Parkinson's disease.
    Goetz CG; Laska E; Hicking C; Damier P; Müller T; Nutt J; Warren Olanow C; Rascol O; Russ H
    Mov Disord; 2008 Apr; 23(5):700-7. PubMed ID: 18175337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine for dyskinesia in Parkinson's disease.
    Crosby NJ; Deane KH; Clarke CE
    Cochrane Database Syst Rev; 2003; 2003(2):CD003467. PubMed ID: 12804468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
    Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R
    Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA
    Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
    Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
    Müller T; Woitalla D; Russ H; Hock K; Haeger DA
    J Neural Transm (Vienna); 2007; 114(8):1023-6. PubMed ID: 17417738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.
    Goetz CG; Wuu J; McDermott MP; Adler CH; Fahn S; Freed CR; Hauser RA; Olanow WC; Shoulson I; Tandon PK; ; Leurgans S
    Mov Disord; 2008 Apr; 23(5):690-9. PubMed ID: 18228568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer.
    Pérez-López C; Samà A; Rodríguez-Martín D; Moreno-Aróstegui JM; Cabestany J; Bayes A; Mestre B; Alcaine S; Quispe P; Laighin GÓ; Sweeney D; Quinlan LR; Counihan TJ; Browne P; Annicchiarico R; Costa A; Lewy H; Rodríguez-Molinero A
    Artif Intell Med; 2016 Feb; 67():47-56. PubMed ID: 26831150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
    Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA
    Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated assessment of bradykinesia and dyskinesia in Parkinson's disease.
    Griffiths RI; Kotschet K; Arfon S; Xu ZM; Johnson W; Drago J; Evans A; Kempster P; Raghav S; Horne MK
    J Parkinsons Dis; 2012; 2(1):47-55. PubMed ID: 23939408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.